LINK Strengthens Presence in Japan with Cosmo Bio and Shigematsu Distribution Agreements
LINK has announced the appointment of two new distributors in Japan — Cosmo Bio and Shigematsu. The companies will work alongside LINK’s current partner, Gene Design, thus strengthening LINK’s presence in this important market and increasing access to its range of innovative reagents for oligo therapeutics and diagnostics.
Cosmo Bio, based in Tokyo, offer a wide range of research reagents and instruments, having been established in the Japanese life science research community for over 30 years. The company represents over 600 domestic and international manufacturers, listing over 10 million products across the entire spectrum of life science research. Mr Yoshiyuki Maki, Director of Cosmo Bio, commented: “We are proud to distribute LINK’s high quality oligonucleotide reagents in the Japanese research market. We have a keen desire to support the development of the life science market, and this new agreement allows us to expand our Advanced Technology product portfolio, further strengthening our position as a leading partner for life science researchers in Japan.”
Based in Osaka, with offices in Tokyo, Tsukuba-city and Minami-aoyama, Shigematsu & Co. have over 50 years’ experience in serving the chemical reagent market, across various fields such as pharmaceuticals, diagnostics, chemicals, foods, electronics, as well as academic and public institutions within Japan. Mr Kenshiro Shigematsu, Director, Marketing & Development at Shigematsu, said: “It gives us great pleasure, and a sense of pride, to be partnering with LINK, and we look forward to helping the company achieve increased success in Japan’s growing oligonucleotide reagent market.”
Dr David Ricketts, CEO of LINK, added: “Japan is an important market for us, but also a complex one. It is essential therefore that we reach customers by more than one channel, to increase choice and value for customers seeking to source and use our products. Adding to the excellent work of our initial partner in Japan, Gene Design, these appointments broaden our reach and underline our ambition and focus to meet customers’ needs on a global scale. We very much look forward to working with our newest partners in Japan to take our business forward.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance